Inherited pathogenic variants (PVs) in the CDKN2A tumor suppressor gene are among the strongest risk factors for cutaneous melanoma. Dysregulation of the p16/RB1 pathway may intrinsically limit the activity of MAPK‐directed therapy due to the interplay between the two pathways. In our study, we assessed, for the first time, whether patients with germline CDKN2A PVs achieve suboptimal results with BRAF inhibitors (BRAFi)+/−MEK inhibitors (MEKi). We compared the response rate of nineteen CDKN2A PVs carriers who received first‐line treatment with BRAFi+/−MEKi with an expected rate derived from phase III trials and “real‐world” studies. We observed partial response in 16/19 patients (84%), and no complete responses. The overall response rate was higher than that expected from phase III trials (66%), although not statistically significant (p‐value = 0.143; 95% CI = 0.60–0.97); the difference was statistically significant (p‐value = 0.019; 95% CI = 0.62–0.97) in the comparison with real‐world studies (57%). The clinical activity of BRAFi+/−MEKi in patients with germline CDKN2A PV was not inferior to that of clinical trials and real‐world studies, which is of primary importance for clinical management and genetic counseling of this subgroup of patients.

Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants

Spagnolo F.;Dalmasso B.;Tanda E.;Ghiorzo P.
2021-01-01

Abstract

Inherited pathogenic variants (PVs) in the CDKN2A tumor suppressor gene are among the strongest risk factors for cutaneous melanoma. Dysregulation of the p16/RB1 pathway may intrinsically limit the activity of MAPK‐directed therapy due to the interplay between the two pathways. In our study, we assessed, for the first time, whether patients with germline CDKN2A PVs achieve suboptimal results with BRAF inhibitors (BRAFi)+/−MEK inhibitors (MEKi). We compared the response rate of nineteen CDKN2A PVs carriers who received first‐line treatment with BRAFi+/−MEKi with an expected rate derived from phase III trials and “real‐world” studies. We observed partial response in 16/19 patients (84%), and no complete responses. The overall response rate was higher than that expected from phase III trials (66%), although not statistically significant (p‐value = 0.143; 95% CI = 0.60–0.97); the difference was statistically significant (p‐value = 0.019; 95% CI = 0.62–0.97) in the comparison with real‐world studies (57%). The clinical activity of BRAFi+/−MEKi in patients with germline CDKN2A PV was not inferior to that of clinical trials and real‐world studies, which is of primary importance for clinical management and genetic counseling of this subgroup of patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/1051750
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact